Skip to main content

FDA AND EMA Approved OXLUMO™ (Lumasiran) for the Treatment of Primary Hyperoxaluria Type 1

Lumasiran
Lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of adults and children with primary hyperoxaluria type 1 (PH1).

Primary hyperoxaluria type 1 (PH1)
PH1 is an ultra-rare orphan disease characterized by excessive oxalate production, which can lead to end-stage renal disease (ESRD) and other systemic complications. PH1 affects approximately 3.5 to 4 individuals per million in Europe and the United States. Heterogeneity in disease manifestation often contributes to delays in diagnosis, with a median time to diagnosis of approximately six years.
PH1 leads to progressive kidney damage, and patients with advanced kidney disease require intensive dialysis to help filter waste products from their blood until they are able and eligible to receive a dual or sequential liver/kidney transplant, an invasive procedure associated with a high risk of morbidity and mortality, and life-long immunosuppression.

Topline Data Highlights (As of 22 OCT2020)
  • Lumasiran Demonstrated a 72 Percent Mean Reduction in Urinary Oxalate and Improvements in Nephrocalcinosis in ILLUMINATE-B Phase 3 Study in Children Under the Age of Six and as Young as Three Months 
  • Alnylam Also Presents New Results from the 12-Month Extension Period of the ILLUMINATE-A Pivotal Study, Showing Sustained Reduction in Urinary Oxalate Levels and Evidence for a Decrease in the Rate of Renal Stone Events in Patients Treated with Lumasiran –
  • Long-Term Results from the Ongoing Phase 2 Open-Label Extension Study Provide Additional Evidence for Sustained Reduction in Urinary Oxalate Levels and Acceptable Safety Profile
Regulatory Update
  • FDA & EMA Approved 
Clinical Studies 

ILLUMINATE-A (NCT03681184)
  • Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1 (PH1).
  • Phase 3
  • Study Type: Randomized
  • Primary Outcome Measures: Percent Change in 24-hour Urinary Oxalate Excretion from Baseline to Month 6 [ Time Frame: 6 months ]
ILLUMINATE-B (NCT03905694)
  • Brief Summary: The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
  • Study Type: Open Label
  • Primary Outcome Measures: Percentage Change in Urinary Oxalate Excretion from Baseline to Month 6 [ Time Frame: Up to 6 months ]


Comments

Popular posts from this blog

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

                                      MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...

MCQs and Answers on cultivation (culture/incubation), Isolation and Identification of microorganisms: Medical Microbiology

40 plus questions - Multiple Choice Questions on Classification, Culture, and Identification of the microorganisms 1. Which of the following microorganism has the cocci cell shapes and sizes arranged usually in tetrad structures? a)  Streptococcus pneumoniae b)  Staphylococcus aureus c)  Chlamydia trachomatis d)  Neisseria meningitidis 2. What are the different growth morphology and cell structures used for the classification of fungi? Select all the correct answers: a) Yeast b) Mold c) Mycelia d) Protozoa 3. Which of the following media is formulated with additional nutrients to support the growth of fastidious or nutritionally demanding bacteria that may not grow well on basic media? a) Differential media b) Enriched media c) Nutrient agar (media) d) Selective media 4. Which of the following metabolic characteristic is a distinguishing characteristic and identification of colonies of  E. coli ? a) Hydrogen sulfide formation b) Indole Formation c) Lactose fe...

MCQs on Bacterial Pathogenesis: Medical Microbiology

Key aspects of Bacterial pathogenesis/ General steps in bacterial pathogenesis Adherence and Colonization  Invasion Immune Evasion Toxin Production Nutrient Acquisition Host Cell Manipulation Inflammation and Tissue Damage                         Multiple Choice Questions on Bacterial Pathogenesis       Figure 1: Phagocyte activity and possible outcomes of phagocyte-bacterial interactions                                     (Source/Reference: Bailey & Scott’s Diagnostic  Microbiology) 1) Which of the following microorganism is the major inhabitant of the human skin? a) Escherichia coli b) Staphylococcus epidermidis c) Staphylococcus aureus d) Streptococcus pyogenes 2) Select all the medically important bacteria which are frequently isolated pathogen  human infections? a) Enteric ba...